Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | HTR2A | P28223 | 2/20 | 0.35 |
| ▸ | HRH1 | P35367 | 2/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1412991 | 0.72 | S100A4 (0.39) | LMNACYP3A4CYP1A2CYP2D6NPC1 | |
| SCHEMBL7342245 | 0.72 | CDC25B (0.39) | LMNACYP3A4CYP1A2CYP2D6NPC1 | |
| SCHEMBL9065440 | 0.67 | MEN1 (0.39) | LMNACYP3A4CYP1A2CYP2D6NPC1 | |
| SCHEMBL10700506 | 0.67 | KMT2A (0.39) | LMNACYP3A4CYP1A2CYP2D6NPC1 | |
| SCHEMBL30839867 | 0.64 | GLS (0.55) | CYP1A2CHRM2CYP2C19MEN1KMT2A | |
| SCHEMBL6540450 | 0.64 | MAOA (0.38) | TAAR1LMNACYP3A4CYP1A2CYP2D6 | |
| SCHEMBL4388842 | 0.64 | GLS (0.55) | CYP1A2CHRM2CYP2C19MEN1KMT2A | |
| SCHEMBL5423240 | 0.63 | CDC25B (0.45) | ATMLMNACYP3A4CYP1A2CYP2D6 | |
| SCHEMBL30297855 | 0.63 | CYP1A2 (0.46) | LMNACYP3A4CYP1A2CYP2D6RAB9A | |
| SCHEMBL13589924 | 0.62 | MEN1 (0.56) | CYP1A2CHRM2CYP2C19MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306134-A1 | Muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-12-10 | — | — | US | disclosed |
| US-7456203-B2 | Muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-20040110229-A1 | Muscarinic receptor antagonists | PNC BANK, NATIONAL ASSOCIATION | 2004-06-10 | — | — | US | disclosed |
| US-6693202-B1 | MULTIBINDING LIGANDS CONTAINING SUCH AS AMINE, AMIDE, ESTER, HYDROXYL, CARBAMATE, UREA AND/OR IMINO FUNCTIONALITY | THERAVANCE, INC. | 2004-02-17 | — | — | US | disclosed |
| US-20030087306-A1 | Methods for identifying novel multimeric agents that modulate receptors | THERAVANCE BIOPHARMA R&D IP, LLC | 2003-05-08 | — | — | US | disclosed |
| EP-1086066-A4 | MUSCARINIC RECEPTOR ANTAGONISTS | ADVANCED MEDICINE INC (US) | 2001-08-08 | — | — | EP | disclosed |
| EP-1086066-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | Advanced Medicine, Inc. (US) | 2001-03-28 | — | — | EP | disclosed |
| EP-1082289-A1 | METHODS FOR IDENTIFYING NOVEL MULTIMERIC AGENTS THAT MODULATE RECEPTORS | Advanced Medicine, Inc. (US) | 2001-03-14 | — | — | EP | disclosed |
| EP-1082289-A4 | METHODS FOR IDENTIFYING NOVEL MULTIMERIC AGENTS THAT MODULATE RECEPTORS | ADVANCED MEDICINE INC (US) | 2001-03-14 | — | — | EP | disclosed |
| WO-1999066944-A9 | METHODS FOR IDENTIFYING NOVEL MULTIMERIC AGENTS THAT MODULATE RECEPTORS | ADVANCED MEDICINE INC (US) | 2000-07-27 | — | — | WO | disclosed |
| WO-1999064043-A9 | MUSCARINIC RECEPTOR ANTAGONISTS | ADVANCED MEDICINE INC (US) | 2000-03-02 | — | — | WO | disclosed |
| WO-1999066944-A1 | METHODS FOR IDENTIFYING NOVEL MULTIMERIC AGENTS THAT MODULATE RECEPTORS | ADVANCED MEDICINE, INC. (US) | 1999-12-29 | — | — | WO | disclosed |
| WO-1999064043-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110229-A1 | Muscarinic receptor antagonists | CHRM3, CHRM5, CHRM2 | TAAR1 149/4885ATM 3029/4885LMNA 4772/4885 |
| US-20090306134-A1 | Muscarinic receptor antagonists | CHRM3, CHRM5, CHRM2 | TAAR1 149/4885ATM 3029/4885LMNA 4772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.